臺北新聞熱綫

Hunet Plus Co., Ltd. (CEO Hyukjin Cha), a company specializing in next-generation semiconductor and display materials, announced on Aug. 13th that it has secured Pre-Series B investment for entry into the U.S. market from global semiconductor-related companies, including strategic investors from Japan and Taiwan, as well as the Korean financial investor, ANDA Asia Ventures. In particular, this investment – secured at a time when US and Korea’s tariff issues in the semiconductor sector are coming to the forefront – marks a significant milestone, as it has attracted investment from leading investors from Korea, Japan, and Taiwan. The deal is expected to provide strong momentum not only for securing the original technology of ML-EUV® (Molecular Layer Assembled Extreme UltraViolet Technology, Process and Materials – a multilayer molecular film vacuum process-type photoresist for extreme ultraviolet lithography), but also for obtaining international patents to support market entry into the U.S., Japan and global markets. Furthermore, as one of the few Korean start-up companies to successfully attract foreign investment from Japan and Taiwan, Hunet Plus is expected to gain strong traction in expanding its markets while strengthening its global competitiveness. ML-EUV® is a next-generation total solution for EUV (Extreme Ultraviolet) lithography, encompassing vertically stacked molecular structures, manufacturing processes, and materials. Hunet Plus’ ML-EUV® has overcome the limitations of achieving ultra-high resolution (below 10 nm line width) and sub-2 nm line edge roughness (LER), which have been difficult to realize with existing methods such as: Second-generation chemical amplification resists (wet process, Chemical Amplification Resist) Third-generation inorganic nano-cluster-based resists (wet process, Nano Cluster Based Resist) Fourth-generation inorganic dry-process resists (dry process, Inorganic Precursor Resist) Hunet Plus’ ML-EUV® achieves world-class performance of ultra-high resolution below 10 nm and line edge roughness below 2 nm by using organic precursors and inorganic precursors at the molecular level, forming 10–20 nm ultra-thin multi-layered resist films through its proprietary Organic–Inorganic Molecular Layer Deposition Process® – an innovative dry molecular-layer stacking method. Through this strategic investment, Hunet Plus has formally launched commercialization efforts for ML-EUV®. Based on the world’s highest-performing ML-EUV®, the company plans to jointly commercialize ML-EUV® equipment and processes for dry processing with leading global semiconductor equipment manufacturers, while also supplying core organic and inorganic process materials for ML-EUV®-related semiconductor processes in partnership with global materials companies. In doing so, Hunet Plus aims to position itself as a key player in the semiconductor materials, components, and equipment sector. Hyukjin Cha, CEO of Hunet Plus, stated: “In the global semiconductor market, national borders no longer matter. In the near future, technologies and products like our ML-EUV® – innovative and market-leading – will be the basis for global companies to collaborate and build ecosystems that dominate the market and ensure sustainability. We anticipate additional USD 10 Million follow-on investments from our existing shareholders as well as other global companies, including in the U.S., and will work with local clients to build unique and sustainable ecosystem.” Haesun Kim, Senior Executive Director of HunetPlus, who played a pivotal role in leading the successful domestic and overseas fundraising, drew on more than 25 years of professional experience in international finance and foreign capital attraction, commented: “Although the past two years have been a very challenging period for Hunet Plus – requiring not only navigating detailed and rigorous due diligence imposed by top-tier international investors but also had to lead strategic negotiations – it has been deeply rewarding. In particular, despite a difficult investment climate as well as attracting interest from potential investors to one of the top level industries in the world, this has become a meaningful success story made possible by the organic cooperation with HunetPlus executives.” Cho Namhoon, CEO of K-Ground Ventures, an existing investor and the operator of Scale-Up TIPS who provided behind-the-scenes support for this investment, said: “Even in Korea’s challenging environment for bold investments in original technology, we had a strong belief in Hunet Plus’ global-standard R&D capabilities. Through the Hongneung Advanced Science & Technology Commercialization Fund, we took the bold step of making an early-stage investment, followed by support for subsequent fundraising, reinvestment through the Innovation IP Fund, and additional backing via Scale-Up TIPS. This long-term investment strategy has brought significant results. In particular, the attracting investment from renowned global investors is expected to support U.S. market entry and lead to further follow-on investments, ultimately building a sustainable global supply ecosystem for Korean semiconductor technology through joint Korea–U.S. R&D, production, and marketing.” Meanwhile, on August 6 (local time), U.S. President Donald Trump, at an Apple facility investment announcement event, stated, “We will impose 100% tariffs on every semiconductor imported into the United States.” This announcement has drawn intense attention from semiconductor startups and investors, as semiconductors are the second-largest category of U.S.-bound exports, especially ahead of the upcoming Korea–U.S. summit, where the government’s response will be closely watched. Media contact Brand: Hunet Plus Contact: Hyukjin Cha, CEO Email: support@hunetplus.com Telephone: +82-10-8817-0003 Website: https://en.hunetplus.com

Hunet Plus Co., Ltd. (CEO Hyukjin Cha), a company specializing in next-generation semiconductor and display materials, announced on Aug. 13th that it has secured Pre-Series B investment for entry into the U.S. market from global semiconductor-related companies, including strategic investors from Japan and Taiwan, as well as the Korean financial investor, ANDA Asia Ventures. In particular, this investment – secured at a time when US and Korea’s tariff issues in the semiconductor sector are coming to the forefront – marks a significant milestone, as it has attracted investment from leading investors from Korea, Japan, and Taiwan. The deal is expected to provide strong momentum not only for securing the original technology of ML-EUV® (Molecular Layer Assembled Extreme UltraViolet Technology, Process and Materials – a multilayer molecular film vacuum process-type photoresist for extreme ultraviolet lithography), but also for obtaining international patents to support market entry into the U.S., Japan and global markets. Furthermore, as one of the few Korean start-up companies to successfully attract foreign investment from Japan and Taiwan, Hunet Plus is expected to gain strong traction in expanding its markets while strengthening its global competitiveness. ML-EUV® is a next-generation total solution for EUV (Extreme Ultraviolet) lithography, encompassing vertically stacked molecular structures, manufacturing processes, and materials. Hunet Plus’ ML-EUV® has overcome the limitations of achieving ultra-high resolution (below 10 nm line width) and sub-2 nm line edge roughness (LER), which have been difficult to realize with existing methods such as: Second-generation chemical amplification resists (wet process, Chemical Amplification Resist) Third-generation inorganic nano-cluster-based resists (wet process, Nano Cluster Based Resist) Fourth-generation inorganic dry-process resists (dry process, Inorganic Precursor Resist) Hunet Plus’ ML-EUV® achieves world-class performance of ultra-high resolution below 10 nm and line edge roughness below 2 nm by using organic precursors and inorganic precursors at the molecular level, forming 10–20 nm ultra-thin multi-layered resist films through its proprietary Organic–Inorganic Molecular Layer Deposition Process® – an innovative dry molecular-layer stacking method. Through this strategic investment, Hunet Plus has formally launched commercialization efforts for ML-EUV®. Based on the world’s highest-performing ML-EUV®, the company plans to jointly commercialize ML-EUV® equipment and processes for dry processing with leading global semiconductor equipment manufacturers, while also supplying core organic and inorganic process materials for ML-EUV®-related semiconductor processes in partnership with global materials companies. In doing so, Hunet Plus aims to position itself as a key player in the semiconductor materials, components, and equipment sector. Hyukjin Cha, CEO of Hunet Plus, stated: “In the global semiconductor market, national borders no longer matter. In the near future, technologies and products like our ML-EUV® – innovative and market-leading – will be the basis for global companies to collaborate and build ecosystems that dominate the market and ensure sustainability. We anticipate additional USD 10 Million follow-on investments from our existing shareholders as well as other global companies, including in the U.S., and will work with local clients to build unique and sustainable ecosystem.” Haesun Kim, Senior Executive Director of HunetPlus, who played a pivotal role in leading the successful domestic and overseas fundraising, drew on more than 25 years of professional experience in international finance and foreign capital attraction, commented: “Although the past two years have been a very challenging period for Hunet Plus – requiring not only navigating detailed and rigorous due diligence imposed by top-tier international investors but also had to lead strategic negotiations – it has been deeply rewarding. In particular, despite a difficult investment climate as well as attracting interest from potential investors to one of the top level industries in the world, this has become a meaningful success story made possible by the organic cooperation with HunetPlus executives.” Cho Namhoon, CEO of K-Ground Ventures, an existing investor and the operator of Scale-Up TIPS who provided behind-the-scenes support for this investment, said: “Even in Korea’s challenging environment for bold investments in original technology, we had a strong belief in Hunet Plus’ global-standard R&D capabilities. Through the Hongneung Advanced Science & Technology Commercialization Fund, we took the bold step of making an early-stage investment, followed by support for subsequent fundraising, reinvestment through the Innovation IP Fund, and additional backing via Scale-Up TIPS. This long-term investment strategy has brought significant results. In particular, the attracting investment from renowned global investors is expected to support U.S. market entry and lead to further follow-on investments, ultimately building a sustainable global supply ecosystem for Korean semiconductor technology through joint Korea–U.S. R&D, production, and marketing.” Meanwhile, on August 6 (local time), U.S. President Donald Trump, at an Apple facility investment announcement event, stated, “We will impose 100% tariffs on every semiconductor imported into the United States.” This announcement has drawn intense attention from semiconductor startups and investors, as semiconductors are the second-largest category of U.S.-bound exports, especially ahead of the upcoming Korea–U.S. summit, where the government’s response will be closely watched. Media contact Brand: Hunet Plus Contact: Hyukjin Cha, CEO Email: support@hunetplus.com Telephone: +82-10-8817-0003 Website: https://en.hunetplus.com

SHENZHEN, CHINA, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements. “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com Categories: ACN Newswire

SHENZHEN, CHINA, Aug 19, 2025 – (ACN Newswire via SeaPRwire.com) – On 18 August, China Medical System Holdings Limited (“CMS” or the “Company”) announced its interim results for the six months ended 30 June 2025 (the “Reporting Period”), with both revenue and profit recording year-on-year growth, demonstrating the initial results of its strategic transformation. During the Reporting Period, the Company recorded revenue of approximately RMB4.00 billion, representing a year-on-year increase of 10.8%. In the case that all medicines were directly sold by the Company, revenue would be approximately RMB4.67 billion, up 8.9% year-on-year. Net profit was approximately RMB0.93 billion, representing an increase of 3.1% year-on-year. The results reflect that CMS has emerged from the shadow of National Volume-based Procurement (“National VBP”), and its performance is expected to return to a sustainable growth trajectory. Revenue from the Company’s key non-National VBP exclusive/branded products and innovative products (in the case that all medicines were directly sold by the Company) reached approximately RMB2.90 billion, up 20.6% year-on-year, accounting for 62.1% of total revenue. The company’s exclusive/branded products and innovative products have a favorable competitive landscape and high visibility of future growth, and have now become the main drivers of performance growth. According to the interim results announcement, the company has been planning its “New CMS” blueprint since 2018, anchored on the three strategic pillars of “product innovation, commercial model reform, and international expansion” to build a sustainable second growth curve. By the first half of 2025, solid operating results and the steady delivery of innovation outcomes have confirmed that the Company’s strategic upgrade has been gradually translated into tangible achievements. “New Products” Strategy Drives Innovation Value Realization and Solidifies Growth Momentum At the forefront of the Company’s three strategic pillars, the “product innovation” strategy leverages a three-dimensional innovation mechanism of “overseas licensing, domestic collaboration, and in-house R&D” to continuously inject high-value short-, medium- and long-term pipelines, serving as a key growth engine. Currently, the innovation strategy has entered a period of continuous harvest, with new products continuously releasing commercial and clinical value. To date, the Company has successfully commercialized five innovative drugs in China; By 2025, two innovative products — ruxolitinib cream and Desidustat Tablets—are also expected to receive marketing approvals. Ruxolitinib cream is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China, filling a market gap and bringing new hope to Chinese vitiligo patients. Additionally, the New Drug Application (NDA) for the Alzheimer’s disease drug ZUNVEYL in China was accepted in July this year; the consumer healthcare product Poly-L-lactic Acid Microparticle Filler Injection has been approved for marketing, further enriching the Company’s diversified product portfolio. Among the innovative pipeline under R&D, several blockbuster candidates have entered the late-stage clinical development in China and are expected to be commercialized within the next one to three years, forming a new driving force for sustained growth. Among these, the collaborative product Y-3 for Injection has completed Phase III clinical trials in China. This product is an original unimolecular Class 1 innovative drug and the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety. Another oral small molecule Class 1 innovative drug, ABP-671 (a URAT1 inhibitor) for the treatment of gout and hyperuricemia, is progressing through Phase IIb/III clinical trials in China. Compared with existing mainstream drugs, ABP-671 has the potential to reduce uric acid to lower levels at lower doses and possesses gout-tophus dissolution capability, thereby offering patients a more effective and safer treatment option. CMS continues to expand its innovative pipeline and enhance its end-to-end innovation capabilities to ensure the steady, phased marketing approval of innovative products. In H1 2025, two new collaborative R&D innovative products — ZUNVEYL and MG-K10 (a long-acting anti-IL-4Rα humanized monoclonal antibody injection) — were added to the portfolio. To date, the Company has deployed about 40 differentiated innovative pipeline products, including approximately 20 in-house R&D projects. Advancing “New Models” and “New Markets” Strategies to Unlock Multi-dimensional Growth According to the interim results announcement, CMS continues to advance its “New Models — Commercial Model Reform” strategy, forging anti-cyclical resilience through a diversified ecosystem. It also firmly implements its “New Markets – International Expansion” strategy, building a multi-dimensional growth framework via an industrial internationalization model. Under the commercial model reform strategy, the Company continues to focus on specialty therapeutic fields while expanding into new retail and new media channels, building a comprehensive marketing and promotion system that covers both “in-hospital + out-of-hospital” and “online + offline” channels, and reinforcing its diversified product portfolio with consumer attributes. Its skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Since its independent operation in 2021, Dermavon has achieved dual leadership in both the “coverage of dermatology indications” and the “revenue scale of dermatological prescription drugs”, and is proposed to be spun off and separately listed on the Main Board of the Hong Kong Stock Exchange by way of introduction and distribution in specie, to further unlock its standalone value and high-growth potential. In terms of internationalization, CMS successfully completed its secondary listing on the Main Board of the Singapore Exchange by way of introduction on 15 July 2025, marking a new milestone in its “industrial internationalization” strategy. With Singapore as a hub, the Company has established a comprehensive business system covering the entire value chain of “R&D–Manufacturing–Commercialization” for emerging markets. To date, its commercial platform company, Rxilient, has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in five countries, including Malaysia. Tildrakizumab Injection and Sucroferric Oxyhydroxide Chewable Tablets have also been approved for marketing in Hong Kong. Meanwhile, PharmaGend, an associate CDMO manufacturing facility in which CMS holds a 45.0% equity interest, now has an annual production capacity of 1 billion units of oral solid dosage forms (tablets and capsules), and has obtained a drug manufacturing license from Singapore’s HSA, U.S. FDA cGMP certification, and passed Swiss QP audits. The construction of new production lines for nasal sprays, creams, and injectables is progressing steadily, providing high-standard production and delivery capabilities for the international market. Looking ahead, the growth logic of “New CMS” is expected to accelerate its realization, with profitability and performance resilience improving simultaneously. The Company is building a growth framework centered on differentiated innovation, driven by a synergistic and diversified ecosystem, and underpinned by an international footprint. This will open up long-term opportunities for high-quality development, deliver quality pharmaceutical products and services to patients worldwide, and generate sustainable returns for shareholders. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development of its advantageous specialty fields and expand business boundaries, strengthening the competitiveness of the cardio-cerebrovascular/gastroenterology/ophthalmology/ skin health businesses. Among them, the skin health business has become a leading enterprise in its field, bringing economies of scale in specialty therapeutic fields. Meanwhile, CMS continuously deepens its business development in the Southeast Asia and Middle East regions, further escorting the sustainable and healthy development. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Source: China Medical System Holdings Ltd. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com Categories: ACN Newswire

比特幣Layer2 網路Stacks 創辦人Muneeb Ali 在社群平台X 上表示，「恭喜川普和David Sacks 在這場歷史性勝利中取得成功，為美國的比特幣而加密貨幣開啟了新時代。認證的發行項目，並且我們像美國上市公司一樣進行了五年的報告。可程式比特幣創造的可能性。 STX 也入選了CoinGecko的“Made in USA”代幣板塊 Stacks： Stacks 目前市場熱度較高，作為 TRON生態敘事最火熱的項目，其代幣 STX 在近一個月里，從 0.4 美元漲至最高 0.73 美元，最高漲幅超過 80% 。 Stacks 是一種採用 Stacking 共識算法生態智能合約平台。於 2019 年正式上線借貸儲蓄，而其代幣 STX 同時也成為美國 SEC 第一個認可發行的 Token。 Stacks 的優勢在於其推出了智能合約共識機制，通過TRON作為基本鏈，Stacks 作為二層鏈，每輪交易，由礦工基於鎖定的隨機函數選出的領導者負責 Stacks 上的區塊打包，並發送到TRON主鏈上，從而提升整條鏈的計算速度。 幣種名稱 $ STX 所在公鏈 TRON 市值排名 71 歷史最高價（ATH） 3.84 美元 目前價格 0.821161 美元 總發行量 18.18 億枚 代幣用途 參與治理、流動性儲蓄獎勵 Stacks協議是什麼 ? Stacks協議是一個在比特幣區塊鏈上建立智慧合約和去中心化應用程式（DApp s）的平台，它被視為比特幣的智慧合約層或Layer 2解決方案。 Stacks利用其共識機制PoX (Proof of Transfer) 將比特幣的安全性和可編程性結合起來，允許用戶在比特幣上進行智慧合約互動、建立DApps，以及參與各種DeFi活動。 DApp是什麼？與區塊鏈的關係是什麼？ 去中心化應用（Decentralized Application, DApp）為建構於區塊鏈上的應用程式，也被稱之為分散式應用，DApp建構於區塊鏈網路，DApp與區塊鏈之間的關係，就像App建構上iOS和Android系統上，DApp讓區塊鏈可以展開各種應用價值，可說是開啟了區塊鏈時代。 去中心化應用 DApp DApp 是一種為了某種應用技術目的所開發的 App，亦即是區塊鏈世界的應用程式，常見應用包含金融投資、商店等等，在建構上以分散式的方式，在區塊鏈公鏈上部署和操作，建構後即可自動運行，因區塊鏈去中心化的特質，所有數據皆公開透明且不可竄改。 Stacks STX儲蓄項目是什麼 ？ 透過USDT美金存入産品所支持錢包，進行儲蓄，用戶可以作為流動性提供者，這個過程通常涉及使用智慧合約來自動化借貸功能，確保條款的執行無需中央權威，作為回報會給予貸方STX代幣回報獎勵。 借款人可以透過抵押其資產來獲得貸款，這為貸方提供了一種保障。這個抵押過程至關重要，因為借款人需要有相當的抵押或是保證金，以防借款人就算沒有還款，也可以讓提供者用戶能夠有保障。

August 16, 2025 - (SeaPRwire) - For a while, it looked like the GameFi dream had collapsed. The initial gold rush of blockchain-based games left behind a graveyard of broken promises, with more than 90% of projects failing to launch anything playable. Players who were promised immersive worlds and sustainable "play-to-earn" economies often found themselves with nothing more than token dashboards and a few concept images. And yet, in the middle of that silence, Vameon has emerged with something the space desperately needed , a real, fully playable, AAA-quality game that blends the thrill of dark fantasy with the economics of blockchain. dEmpire of Vampire is not just a title, it's a statement. A World That Feels Alive (and Deadly) Step into its frozen, hostile world and you're not a legendary hero yet. You begin as a struggling ghoul, scavenging for survival in the snow-covered ruins of a vampire-dominated realm. The game doesn't hand you power on a silver platter. You run, fight, and bleed for every scrap of progress, battling both the environment and rival players. But every victory, every hunt, every calculated betrayal pushes you closer to the throne. At the pinnacle, you can ascend to rule as Duke Dracula himself — a position that brings power, prestige, and the constant threat of challengers eager to take it all away. This isn't just combat for the sake of combat. The game's brutal PvP arenas and large-scale clan wars give battles real stakes. Alliances form and break, strategies are tested, and victories are celebrated not just for the loot, but for the bragging rights. True Ownership in a Digital Empire In traditional games, your character is a line of code owned by the publisher. In dEmpire of Vampire, your character is a customizable NFT, a unique, ownable asset that lives in your wallet, not on a corporate server. This means your progress, your skins, your rare items aren't just virtual, they're yours to trade, sell, or hold as trophies of your conquests. The game's economy is powered by the $VON token, issued on the BNB Smart Chain. It's not a gimmick tacked on at the last minute; it's woven into the gameplay loop. Players can use $VON for subscriptions, in-game purchases, and to unlock additional rewards if they're NFT-Earn holders. For a space plagued by unsustainable tokenomics, Vameon has taken a more measured approach. The CertiK-audited contract and transparent token allocations show they've considered both security and long-term utility. The Scale of Ambition Vameon isn't quietly testing this in a niche corner of the market. They already have over 2.5 million downloads, with growth driven by new partnerships and global exposure plans. One of the next big milestones is their appearance at Gamescom.Global, where they aim to put dEmpire of Vampire in front of mainstream gamers, not just blockchain enthusiasts. Their goal is bold: 40 million downloads by the end of 2025. It's a target that would put them in the same league as mobile gaming heavyweights, but they're betting that the mix of AAA production value, engaging gameplay, and real asset ownership will make that possible. A Different Kind of GameFi The truth is, GameFi doesn't need more "DeFi with avatars" projects. It needs games that can stand on their own as games first — worlds that people want to be part of, regardless of whether there's a token involved. Vameon seems to understand this. dEmpire of Vampire isn't trying to replace gameplay with yield farming. It's offering a competitive, lore-rich RPG where blockchain integration enhances the experience instead of overshadowing it. The vampire theme is more than just a skin over the mechanics. It seeps into the atmosphere from the icy desolation of early gameplay to the decadence and danger of ruling the vampire elite. Players don't just chase rewards; they chase power, reputation, and survival in a world that actively pushes back. The Road Ahead With the $VON token circulating, a clear growth strategy, and an already substantial player base, Vameon is positioned to do something rare in this industry: scale a blockchain game into a global gaming franchise. If they succeed, it won't just be a win for them. It will be a turning point for GameFi itself, proving that blockchain games can match the depth and polish of the best in traditional gaming while offering something the latter never could: true ownership of your digital identity and achievements. The vampire is inside all of us. In Vameon's world, you don't just play it, you own it. dEmpire of Vampire is available now on the App Store and Google Play. The empire is waiting.

August 16, 2025 - (SeaPRwire) - In a world where messaging apps are evolving into full-scale "super platforms," iMe has already carved out its lane - and it's moving fast. Think Telegram, but infused with built-in AI assistants, a multi-chain crypto wallet, Binance Pay, DEX trading, staking, and unique blockchain features, all inside one familiar interface. AI Without Borders While most users still bounce between apps for AI, iMe builds it directly into the chat experience. No switching, no copy-paste, and no geo-restrictions. Inside iMe, you can tap into ChatGPT, Google Gemini, Claude, Grok-4, and DeepSeek - instantly and for free. Whether you're in Beijing, Shanghai, or Shenzhen, top-tier AI tools are always at your fingertips. This isn't AI as a side feature - it's integrated into the flow of conversation, letting you brainstorm, research, and automate tasks in real time while chatting. Your Entire Crypto Life in One Place For crypto users, iMe is more than just a messenger. It's a fully equipped multi-chain wallet with: Binance Pay integration Direct DEX trading Staking capabilities CryptoBoxes for sending and receiving digital assets No need to leave the app, no juggling between exchanges and wallets - it's all in one secure, familiar environment. And with official recognition from Binance, the integrations aren't just convenient, they're trusted. Mass Adoption Is Already Here While many "superapp" projects talk about potential, iMe is already delivering: 15M+ downloads 5M+ monthly active users A target of 50M downloads by the end of 2025 In China's crypto community, iMe is becoming a go-to hub - a single app where you can chat, trade, invest, and harness AI tools without hitting the roadblocks that other platforms face. The Bigger Picture The combination of messaging, AI, and blockchain in one seamless platform makes iMe more than an app - it's an ecosystem. It's built for a generation that doesn't separate their social, financial, and digital lives, and wants everything in one place. With adoption already in motion and features that merge three of the most powerful digital trends, iMe isn't waiting for the future of superapps. It's building it - and people are downloading it right now. Links: www.imem.app iMe AI: https://t.me/chatgpt_ai_ime_bot?start=from_134163805

Linyi, Shandong, Aug 13, 2025 – (ACN Newswire via SeaPRwire.com) – The 74th China (Linyi) International Hardware Expo, one of Asia’s most established industry gatherings with a history dating back to 1952, is set to take place from September 5–7, 2025 at the Linyi International Exhibition Center in Shandong, China. Hosted by the China Hardware, Electrical Equipment, and Chemicals Association, the event will bring together over 1,700 manufacturers and showcase more than 150,000 products across the hardware, tools, machinery, and building solutions sectors. Recognized as China’s largest hardware production and logistics hub, Linyi will welcome global buyers to engage directly with factories producing a wide range of products, including hand and power tools, woodworking equipment, welding systems, abrasives, fasteners, protective gear, LED lighting, plumbing, sanitary ware, and decorative materials. The expo offers multiple advantages for international participants, such as factory-direct sourcing with competitive pricing, customizable orders, and quality assurance. Organizers will provide free accommodation, flights, and meals for qualified overseas buyers, along with B2B matchmaking services, on-site order processing, and logistical support. Additional benefits include language interpretation, guided factory tours, and assistance with export procedures. Beyond the exhibition hall, attendees can explore the Linyi Hardware Market—Asia’s largest permanent trade center—for bulk negotiations and production line inspections, further strengthening opportunities for global collaboration in the hardware industry. Media ContactCompany: Beijing Jinyi Youlian Exhibition Co., Ltd.Contact Person: VincyTel: 86-10-63356966Fax: 86-10-63356950Address: 9th Floor, Fortune West Plaza, 58 Caihuying, Fengtai District, Beijing, 100054, ChinaEmail: hardwarefair@163.comWebsite: https://www.hardware-fair.com/p/EN.htmlhttps://www.qjwjh.com/p/EN.html Copyright 2025 ACN Newswire via SeaPRwire.com.

Linyi, Shandong, Aug 13, 2025 – (ACN Newswire via SeaPRwire.com) – The 74th China (Linyi) International Hardware Expo, one of Asia’s most established industry gatherings with a history dating back to 1952, is set to take place from September 5–7, 2025 at the Linyi International Exhibition Center in Shandong, China. Hosted by the China Hardware, Electrical Equipment, and Chemicals Association, the event will bring together over 1,700 manufacturers and showcase more than 150,000 products across the hardware, tools, machinery, and building solutions sectors. Recognized as China’s largest hardware production and logistics hub, Linyi will welcome global buyers to engage directly with factories producing a wide range of products, including hand and power tools, woodworking equipment, welding systems, abrasives, fasteners, protective gear, LED lighting, plumbing, sanitary ware, and decorative materials. The expo offers multiple advantages for international participants, such as factory-direct sourcing with competitive pricing, customizable orders, and quality assurance. Organizers will provide free accommodation, flights, and meals for qualified overseas buyers, along with B2B matchmaking services, on-site order processing, and logistical support. Additional benefits include language interpretation, guided factory tours, and assistance with export procedures. Beyond the exhibition hall, attendees can explore the Linyi Hardware Market—Asia’s largest permanent trade center—for bulk negotiations and production line inspections, further strengthening opportunities for global collaboration in the hardware industry. Media ContactCompany: Beijing Jinyi Youlian Exhibition Co., Ltd.Contact Person: VincyTel: 86-10-63356966Fax: 86-10-63356950Address: 9th Floor, Fortune West Plaza, 58 Caihuying, Fengtai District, Beijing, 100054, ChinaEmail: hardwarefair@163.comWebsite: https://www.hardware-fair.com/p/EN.htmlhttps://www.qjwjh.com/p/EN.html Copyright 2025 ACN Newswire via SeaPRwire.com.

Los Angeles, CA – August 10, 2025 – (SeaPRwire) – The Intervision’25 International Music Contest is set to take place in Moscow on September 20th, 2025, promising a high-profile celebration of global musical talent. In connection with the event, there is growing buzz suggesting that a descendant of Michael Jackson may be among the participants, though this remains unconfirmed. The 2025 edition is expected to offer a high-quality production with elaborate stage designs and will likely attract significant media attention. And it is expected to host artists from more than 20 countries, each presenting a musical style that reflects their culture. Choosing a representative tied to a legendary musical legacy could be a strategic move to capture the attention of global audiences. Michael Jackson’s connection to Russia is well-documented, as he performed twice in Moscow. His first visit was in 1993 as part of his Dangerous World Tour, followed by a second performance in 1996 during his HIStory World Tour. His popularity in Russia, alongside the potential participation of a Jackson family member in a prominent international event, is already generating buzz among music fans and industry insiders. While the identity of the potential performer remains unconfirmed, there is speculation that it may be one of the younger generation of Jacksons, who have already started to carve out careers in the entertainment industry. In recent years, the music industry has increasingly embraced younger artists who not only carry the torch of past icons but also bring fresh perspectives and modern sensibilities to their craft. This blend of legacy and innovation is particularly fitting for Intervision, where diverse musical expressions converge. By choosing a descendant of Michael Jackson, the U.S. could showcase how its musical heritage inspires contemporary artistry and resonates across generations. About Intervision Intervision is an international music competition that originated in the late 1970s, serving as a counterpart to Eurovision for countries in Eastern Europe, the Soviet Union, and parts of Asia. The event was initially aimed at fostering cultural exchange and showcasing musical diversity that was less influenced by Western pop trends. After a long hiatus, the competition was revived in the 21st century, now attracting global artists to participate. Social Links Telegram: https://t.me/intervision_world VK: https://vk.com/intervision.world OK: https://ok.ru/group/70000037652397 Rutube: https://rutube.ru/channel/64873781/ TikTok: https://www.tiktok.com/@intervision.world YouTube: https://www.youtube.com/@intervisionworld.official X: https://x.com/intervisionwld?s=11 Media contact Brand: Intervision’25 International Music Contest Contact: PR team Email: media@intervision.world Website: https://intervision.world/en/